Page 86«..1020..85868788..100110..»

Category Archives: Cell Therapy

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic … – The Scientist

Posted: June 14, 2017 at 8:45 pm

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic ...
The Scientist
Cambridge, UK, 14 June 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the Company), the world leader in the application of gene editing technologies, today announces progress of its gene and cell therapy platform for contract service and ...

and more »

More:
Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic ... - The Scientist

Posted in Cell Therapy | Comments Off on Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic … – The Scientist

Evolving Education Initiative Keeps Nurses Up-to-Date on CAR T Cell Therapy Best Practices – Oncology Nurse Advisor

Posted: June 14, 2017 at 8:45 pm

Evolving Education Initiative Keeps Nurses Up-to-Date on CAR T Cell Therapy Best Practices
Oncology Nurse Advisor
DENVER Use of a multidisciplinary education initiative effectively prepared nursing and clinical staff for the challenges of managing care and follow-up of patients undergoing chimeric antigen receptor T cell (CAR-T) therapy across multiple ...

See original here:
Evolving Education Initiative Keeps Nurses Up-to-Date on CAR T Cell Therapy Best Practices - Oncology Nurse Advisor

Posted in Cell Therapy | Comments Off on Evolving Education Initiative Keeps Nurses Up-to-Date on CAR T Cell Therapy Best Practices – Oncology Nurse Advisor

Global Autologous Cell Therapy Market – Analysis, Technologies & Forecasts to 2021 – Increasing Demand for Effective … – Business Wire (press…

Posted: June 14, 2017 at 8:45 pm

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Autologous Cell Therapy Market 2017-2021" report to their offering.

The global autologous cell therapy market to grow at a CAGR of 23.39% during the period 2017-2021.

The report, Global Autologous Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

The latest trend gaining momentum in the market is private funding will fuel market growth. The increasing investments from private enterprises will likely change the market dynamics. Many vendors are investing in production or manufacturing facilities to improve their production or manufacturing expertise. They are also focusing on establishing new business units or companies to penetrate the market further.

According to the report, one of the major drivers for this market is increasing demand for effective drugs for cardiac and degenerative disorders. There has been an increased demand for providing effective drugs for cardiac and degenerative disorders globally. Prior to the advent of autologous cell therapies, there was no effective drug to repair a damaged heart. The discovery of possible cardiac autologous cells opened new possibilities for repairing damaged cardiac tissue caused by acute myocardial infarction or coronary artery disease.

Key vendors

Other prominent vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Pipeline Landscape

PART 06: Market landscape

PART 07: Market segmentation by application

PART 08: Market Segmentation by therapy

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/633cdq/global_autologous

Originally posted here:
Global Autologous Cell Therapy Market - Analysis, Technologies & Forecasts to 2021 - Increasing Demand for Effective ... - Business Wire (press...

Posted in Cell Therapy | Comments Off on Global Autologous Cell Therapy Market – Analysis, Technologies & Forecasts to 2021 – Increasing Demand for Effective … – Business Wire (press…

Stem Cell Therapy Offers Hope for Multiple Sclerosis Remission – Healthline

Posted: June 14, 2017 at 4:47 am

By combining an experimental stem cell treatment with a nanoparticle delivery system, researchers may eventually stop MS and other autoimmune diseases.

An innovative stem cell therapy could change how we treat multiple sclerosis (MS), but are we any closer to a cure?

The work of Dr. Su Metcalfe, founder and chief scientific officer of the biotech company LIFNano, appears to be breathing new life into that hope.

Metcalfe and her team developed a way to fight MS by using the bodys own natural mechanisms but it hasnt been tested in humans yet.

MS is an inflammatory and neurodegenerative autoimmune disease that can result in an array of neurological symptoms including fatigue, muscle spasms, speech problems, and numbness. It is caused by the immune system attacking myelin, the insulating coating that runs along the outside of nerve cells. The result is damage to the brain and central nervous system.

The disease currently affects roughly 2.5 million people worldwide. About 200 new cases are diagnosed each week in the United States.

LIFNano uses a new treatment based on LIF a stem cell protein that forms naturally in the body to signal and regulate the immune systems response to myelin.

LIF, in addition to regulating and protecting us against attack, also plays a major role in keeping the brain and spinal cord healthy, Metcalfe recently told Cambridge News.

In fact it plays a major role in tissue repair generally, turning on stem cells that are naturally occurring in the body, making it a natural regenerative medicine, but also plays a big part in repairing the brain when its been damaged, she said.

Metcalfe has spent years studying LIF, but only recently realized its potential for treatment likening it to an on/off switch for the immune system.

However, once she discovered its potential, there were almost immediate problems in its application. One of the earliest was how quickly LIF breaks down once it is administered into the body.

If you try just to inject it into a patient, it dissipates or disappears in about 20 minutes, Olivier Jarry, CEO of LIFNano, told Healthline.

That makes it unusable in a clinic. You would have to have some kind of pump and inject it continually.

A breakthrough came for Metcalfe when she took findings from her studies of LIF and applied them to nanotechnology. The treatment she is now developing relies on nanospheres derived from a well-established medical polymer known as PLGA, which is already used in materials like stitches. And because it is biodegradable, it can be left to dissolve inside the body.

Storing LIF inside these PLGA nanospheres before administering them into the bloodstream allows for a sustained dose over the course of several days.

The process differs significantly from the current drugs used to treat MS. These treatments most often fall under the category of drugs known as immunosuppressors, which inhibit the bodys overall immune system response.

LIF is theoretically much more precise than immunosuppressors, and should keep the immune system functioning against harmful infections and disease.

Were not using any drugs, said Metcalfe. Were simply switching on the bodys own systems of self-tolerance and repair. There arent any side effects because all were doing is tipping the balance. Autoimmunity happens when that balance has gone awry slightly, and we simply reset that.

The team cautions that LIF therapy is still several years away.

While some outlets have run wild with Metcalfes research, announcing that a cure for MS is right around the corner, those headlines are speculative.

Some MS advocacy groups have even made public statements calling coverage of her work premature and irresponsible.

Jarry told Healthline that LIFNano is expecting to enter FDA phase I trials in 2020. This would be the first time that it is used in human subjects. But even if the treatment proves to be safe and effective, the soonest it could be on the market is 2023, he estimated.

The main focus of LIF therapy is now on MS. But it has potential for treating other autoimmune diseases including psoriasis and lupus.

We are optimistic in the sense that we may provide a long-term remission for patients with MS, said Jarry.

Is it a cure? Wed love at some point to use the term cure, but we are very cautious.

Continued here:
Stem Cell Therapy Offers Hope for Multiple Sclerosis Remission - Healthline

Posted in Cell Therapy | Comments Off on Stem Cell Therapy Offers Hope for Multiple Sclerosis Remission – Healthline

For experimental cancer therapy, a struggle to ensure supply keeps up with demand – Science Magazine

Posted: June 14, 2017 at 4:47 am

The year-old Novartis-Penn Center for Advanced Cellular Therapeutics in Philadelphia supplies cancer fighting T cells to multiple hospitals, visible out the window.

CANNONDESIGN

By Jennifer Couzin-FrankelJun. 13, 2017 , 3:15 PM

A transformative cancer therapy based on modified immune cells has lured doctors, companies, and patients alike, but many are hitting a frustrating roadblock: generating enough of these chimeric antigen receptor (CAR)-T cells to meet surging demand. The situation is fluid, with shortages cropping up in some places and easing in others. Doctors, meanwhile, are grappling with how best to distribute the experimental therapy among very sick patients in clinical trials.

How do I allocate the resource in a way thats fairest to everybody and that treats the most patients and potentially saves the most lives? asks Stephan Grupp, a pediatric oncologist at the Childrens Hospital of Philadelphia (CHOP) in Pennsylvania. Grupp has offered CAR-T therapy to more than 150 children with late-stage acute lymphoblastic leukemia (ALL)and worries that because of supply limitations, he cant help more.

CAR-T cell therapy took the cancer world by storm in the summer of 2010. It involves removing a patients immune cells, genetically modifying them to fight their particular cancer, then transfusing them back. The approach is riskysome have even died from itbut for blood cancers in particular, its been remarkable, saving patients at the 11th hour and keeping some in remission for years.

For patients, getting the most anticipated new treatments is never easy. Clinical trials are tightly controlled and not everyone is eligible. But for this personalized approach, the difficulties are multiplied. From the beginning, CAR-T cells were tough to produce. Unlike a drug, each batch is designed for a specific patient. Production involves genetic engineering and working with live cells, and it is still mostly done by hand, by highly trained technicians. Preparing cells for a single patient can take weeks and cost tens of thousands of dollars.

The demand took off when doctors began reporting impressive results in leukemia and, later, lymphoma, with response rates ranging from 40% to 50% in lymphoma to more than 90% in some leukemias. More researchers joined the fray, keen to test CAR-T therapy in patients with other cancers. Companies joined in, too, anticipating a burgeoning market. Dozens of trials are underway, and two CAR-T cell products, for childhood and young adult ALL and aggressive B-cell lymphoma, may be approved later this year by the U.S. Food and Drug Administration (FDA).

The promise of this stuff outpaced the typical approach to development, Grupp says. With about 50 scientists and technicians working furiously to produce cell therapies for trials throughout the University of Pennsylvania (UPenn), CHOP can treat about five children each month. That number rules my life, says Grupp, who receives two or three calls a week about yet another child whose parents hope to secure the therapy. He engages in a delicate dance, trying to keep some children stable while treating the sickest, before theyre too sick to benefit. So far, he believes, he has reached everyone referred from within the United States in time.

At the National Cancer Institute in Bethesda, Maryland, hematologist James Kochenderfers waiting list is driven by the two or three CAR-T cell products a month hes able to secure from the agencys facility. Thats not enough to accommodate all the adults eligible for the seven CAR-T trials hes running in blood cancers. He usually enrolls on a first-come, first-served basis.

Demand for the therapy is also spurring competition for the researchers and technicians who create the cells. Everyone is losing [people] to everyone else, says immunologist Bruce Levine of UPenn, who directs the cell production facility. He guards against the poaching of his staff by companies that can pay a higher salary, in part by stressing a connection with patients at the hospitals he can see out his window. We have patients come over on a regular basis who received cells made in UPenns facility. No company can offer that.

One center that says its keeping up with demand is Baylor College of Medicine in Houston, Texas, in part because of a stroke of luck. We kind of overbuilt, opening a vast facility in 2010, says Adrian Gee, who runs it. Seattle Childrens Hospital in Washington recently broke ground on a building that in a few years will triple or quadruple its cell therapy capacity, now about 10 batches of CAR-T cells a month.

Another way to generate cells for more patients is to shorten the time it takes to make them. Right now the time from vein to vein ranges from about 2 to 4 weeks, depending partly on the technique. Scientists are experimenting with more efficient approaches. Rebecca Gardner, a pediatric oncologist at Seattle Childrens, says the hospital is shifting to one that shaves a week or two off its 3- to 4-week time frame.

Ultimately, the supply problem can be solved with money, says Ronald Levy, a lymphoma specialist at Stanford University in Palo Alto, California. And no one has more money to funnel into CAR-T therapy than the companies. Novartis, for example, spent $43 million on a manufacturing facility in Morris Plains, New Jersey, and last week it released results from a lymphoma trial in which cells were frozen and flown to and from patients in 10 countries.

But some researchers wonder whether the companies will be ready to accommodate the surge in demand expected if FDA approves the first CAR-T therapies. The strain on supplies would increase if doctors want to offer CAR-T therapy to patients off-label, to those who fall outside the approved indication but might still benefit. Unlike a traditional drug, every order needs to be placed through the companiesand its not clear whether they and FDA will support off-label use. If Novartiss product is approved for leukemia patients up to 28 years old, say, and you have a 28.1-year-old, does that mean you cant treat them? asks David Maloney, an oncologist and immunotherapist at the Fred Hutchinson Cancer Research Center in Seattle. I dont know whats going to happen.

For now, scientists are pondering how to best allocate the therapy. At Seattle Childrens, pediatrician and bioethicist Douglas Diekema was drafted by colleagues to offer ethical guidance on what to do if the hospital cant make enough CAR-T cells for everyone in planned trials in brain and other solid tumors, as well as more leukemia trials. A year from now well probably have six to seven trials, up from three today, Gardner says.

Last month, Diekema and his colleagues published a paper online in the Journal of Medical Ethics describing a triage plan for selecting volunteers for CAR-T trials. They argued that, when possible, doctors should focus on the likelihood and magnitude of benefit, treating the sickest patients first. In a second paper still under review, the team will discuss how to allocate CAR-T therapy across clinical trials. There, the ethical calculus is different, including whether the disease affects many people versus just a few.

I did get a 10 p.m. phone call recently, saying we may need to implement the patient allocation strategy, Diekema says. But the hospital, in the end, managed to get the cells to everyone. We dodged it this time, Diekema says. Now, like many others, hes waiting for the next crunch.

More:
For experimental cancer therapy, a struggle to ensure supply keeps up with demand - Science Magazine

Posted in Cell Therapy | Comments Off on For experimental cancer therapy, a struggle to ensure supply keeps up with demand – Science Magazine

Former Kilkenny star Richie Power hoping stem-cell therapy can fix his knee – The Irish Sun

Posted: June 14, 2017 at 4:47 am

Power was forced to retire from inter-county hurling with the injury two years ago at the age of 29

RICHIE POWER hopes radical new stem-cell therapy in Croatia can fix his battered knee.

The eight-time All-Ireland medallist with Kilkenny retired in the wake of the 2015 Liam MacCarthy triumph at the age of just 29.

Power had three operations on his left knee that year alone and admits rushing back too soon ultimately ended his career.

The speedy attacker got back to Croke Park in February with AIB All-Ireland intermediate club champions Carrickshock.

But he has not played for them since and his quality of life has suffered with his knee causing him constant pain.

Ex-Kilkenny hurler David Byrne, who works with an American company linked to a hospital in Zagreb, put Power on the stem-cell trail.

Power said: The process is about regenerating cartilage in the left knee.

They take some good cartilage from the right knee, bring it into the lab and more or less clone it.

Then they inject it back into your left knee and you are hoping then that the blood will run to it and regenerate there.

From what I gather, youre not looking at a huge period of time out.

You have two or three months to help it and they bring you back over every three months for a check-up to see if its working.

The big issue is that I dont think theres anyone who has stood over it and said, Yeah, it definitely works, because they are waiting to see five, ten, 15 years down the line as to how it helps.

The feedback has been positive. Its worth a try.

The former Cats star is not looking to revive his county career though even if Kilkenny could do with him.

He is simply looking for a better quality of life and to extend his club career by a few more years.

Power added: If I dont get anything done in Croatia and if I decide to go back playing for another year or two and keep struggling through, then Im probably looking at a knee replacement by the time Im 40.

Im only 31 so its not something I want to face at such a young age.

It is just to try to give me an extra 15 or 20 years with my own knee.

If they can do that then great, it will be well worth it. If not, then I need to make a decision and maybe hang up the boots altogether.

See the article here:
Former Kilkenny star Richie Power hoping stem-cell therapy can fix his knee - The Irish Sun

Posted in Cell Therapy | Comments Off on Former Kilkenny star Richie Power hoping stem-cell therapy can fix his knee – The Irish Sun

Stem Cell Therapy Becomes Law in Texas – PR Newswire (press release)

Posted: June 14, 2017 at 4:47 am

"At StemGenex, we are committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells," said Alexander. "Specifically, we use adipose-derived adult stem cell therapy for patients battling conditions such as Multiple Sclerosis, Parkinson's disease, COPD, Rheumatoid Arthritis and Osteoarthritis. We are also committed to the science of stem cell therapy and sponsor five clinical outcome studiesregistered with theNational Institute of Health (NIH) for these diseases."

"What I personally witnessed before the start of StemGenex were patients who had exhausted conventional medical treatments but wanted to try alternative therapies. I was one of them, suffering from severe Rheumatoid Arthritis. Ihad only three options; I could seek a clinical trial, travel to outside of the U.S. to try alternative therapies such as stem cell treatment or petition the FDA for access to drugs under the agency's "expanded access," or "compassionate use" program. Now, new state laws like the one just passed in Texas, built on model legislation from the Goldwater Institute in Arizona, will allow doctors and patients to make their own informed decisions on treatments that have cleared the safety phase of FDA testing."

Last year, in a move that was seen by some as a response to "Right to Try" laws, the 21st Century Cures Act, a landmark piece of legislation focused on medical innovation and medical research, was signed into law by President Obama. This Act provides the FDA with the flexibility to accelerate how it evaluates regenerative medicine treatments, such as stem cell therapies, while maintaining its high standards of safety and efficacy.

"We're on the cusp of a major change on how patients can access stem cell therapy," saidAlexander. "Today, new treatments and advances in research are giving new hope to people affected by a wide range of autoimmune and degenerative illnesses," said Alexander. "StemGenex Medical Group is proud to offer the highest quality of care and to potentially help those with unmet clinical needs improve their quality of life."

ABOUT StemGenex Medical Group

StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment,StemGenex sponsors five clinical outcome studiesregistered with theNational Institutes of Health (NIH) for Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.

Contact: Jamie Schubert, Director of Media & Community Relations jschubert@StemGenex.com, (858) 242-4243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-becomes-law-in-texas-300472809.html

SOURCE StemGenex Medical Group

http://www.stemgenex.com

Excerpt from:
Stem Cell Therapy Becomes Law in Texas - PR Newswire (press release)

Posted in Cell Therapy | Comments Off on Stem Cell Therapy Becomes Law in Texas – PR Newswire (press release)

July hearing for pioneering CAR-T cell therapy – The Pharma Letter – The Pharma Letter (registration)

Posted: June 11, 2017 at 3:41 pm

The US Food and Drug Administrations (FDA) Oncologic Drugs Advisory Committee will review the Biologics

To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.

BiotechnologyCTL019Focus OnImmuno-oncologyNovartisOncologyOxford BioMedicaRegulationUS FDAUSA

Access The Pharma Letter's latest news free for 7 days

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Click here to take a free trial

Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year

Click here to subscribe

Go here to see the original:
July hearing for pioneering CAR-T cell therapy - The Pharma Letter - The Pharma Letter (registration)

Posted in Cell Therapy | Comments Off on July hearing for pioneering CAR-T cell therapy – The Pharma Letter – The Pharma Letter (registration)

Stem Cell Therapy: Repair and Regenerate Our Bodies – Live … – Live Trading News

Posted: June 10, 2017 at 3:44 am

Stem Cell Therapy: Repair and Regenerate Our Bodies

$USRM

Stem Cells 101: The primary purpose of stem cells is to maintain, heal and regenerate tissues wherever they reside in the body. This is a continuous process that occurs inside the body throughout life. If we did not have stem cells, our lifespan would be about 1 hour, because there would be nothing to replace exhausted cells or damaged tissue.

Notably: any time the body is exposed to any sort of toxin, the inflammatory process causes stem cells to swarm the area to repair the damage.

While it is easy to think of stem cell therapy as some sort of magic, it is wise to implement strategies that nourish and optimize the stem cells we already have in your body.

Dr. Kristin Comella, a notable Stem Cell innovator, writes: You have to create an appropriate environment for these cells to function in. If you are putting garbage into your body and youre constantly burdening your body with toxins, your stem cells are getting too distracted trying to fight off those toxins. By creating an appropriate environment, optimizing your diet and reducing exposure to toxins, that will allow the stem cells that were putting in to really home in and focus on the true issue that were trying to treat.

The other thing weve discovered over the years is that [stem cell therapy] is not the type of thing where you take one dose and youre cured forever. Your tissues are constantly getting damaged Youre going to have to repeat-dose and use those stem cells to your advantage.

When you think about a lizard that loses its tail, it takes two years to grow back the tail. Why would we put unrealistic expectations on the stem cells that were trying to apply to repair or replace damaged tissue? This is a very slow process. This is something that will occur over months and may require repeat dosing.

Stem cells historically were isolated from bone marrow, and have been used for bone marrow transplants for cancer patients since the 1930s. However, we can get stem cells from just about any tissue in the body, every tissue contains stem cells.

Actually our marrow has very low amounts of mesenchymal stem cells, which are now believed to be the most important, from a therapeutic perspective.

Mesenchymal stem cells help trigger an immunomodulatory response or a paracrine effect, which means they send signals out to the rest of the body, calling cells to the area to help promote healing.

What weve discovered in more recent years is that a more plentiful source of stem cells is actually your fat tissue. [Body] fat can contain up to 500 times more cells than your bone marrow, as far as these mesenchymal type stem cells go.

One thing thats also critically important when youre talking about isolating the cells is the number of other cells that are going to be part of that population. When youre isolating a bone marrow sample, this actually is very high in white blood cells, which are pro-inflammatory, Ms. Comella writes.

White blood cells are part of the human immune response.

When an injury occurs, or a foreign body enters our system, white blood cells will attack. Unfortunately, white blood cells do not discriminate, and can create quite a bit of damage as they clean the area out.

Stem cells, in particular the mesenchymal cells, quiet down the white blood cells and then start the regeneration phase, which leads to new tissue. Bone marrow tends to be very high in white blood cells and low in the mesenchymal cells.

So, isolating stem cells from fat tissue is preferred not only because its easier on the patient, but fat also contains a higher population of mesenchymal cells and fewer white blood cells.

The benefit also of isolating [stem cells from] fat is that its a relatively simple procedure. Theres typically no shortage of fat tissue, especially in Americans, Dr.. Comella says. Also, as you age, your bone marrow declines with regards to the number of cells in it, whereas the fat tissue maintains a pretty high number of stem cells, even in older individuals.

Fat can be successfully harvested from just about anyone, regardless of their age or how thin they are. The procedure is done under local anesthesia, meaning that the patient stays awake. We can harvest as few as 15 cubic centimeters of fat, which is a very small amount of fat, and still get a very high number of stem cells.

A stem cell procedure can cost anywhere from $5,000 15,000, depending on what one is having done, and rarely if ever will insurance cover it.

Still, when compared it to the cost of long-term medications or the out-of-pocket cost of getting a knee replacement, stem cell therapy may still be a less expensive alternative.

Also, a single extraction will typically yield enough stem cells for 20 to 25 future treatments, should one decide to store his/her stem cells for future needs.

I think its accessible for patients, Dr.. Comella says. Its an out-patient procedure. You plan to be in clinic for about two hours; no real limitations afterwards, just no submerging in water, no alcohol, no smoking for a week. But other than that, patients can resume their normal activities and go about their regular daily lives.

She notes that patients who eat a very healthy diet, focusing on Organic and grass fed foods, have body fat that is very hearty and almost sticky, yielding high amounts of very healthy stem cells.

We can grow much better and faster stem cells from that fat than [the fat from] somebody who eats a grain-based diet or is exposed to a lot of toxins in their diet, she says. Their fat tends to be very fluffy, buttery yellow. The cells that come out of that are not necessarily as good a quality. Its just been very interesting. And of note, patients that are cigarette smokers, their fat is actually gray-tinged in color. The stem cells do not grow well at all.

What has been described above is whats called an autologous donation, meaning a person is getting the stem cells from oneself. A number of companies provide non-autologous donations using cells harvested from other people, typically women, like amniotic or embryonic mesenchymal cells.

This is an important distinction.

There are now just a couple of studies that have been published comparing an autologous source, meaning cells from you own body, to an allogeneic source, meaning cells from someone else.

So far, what has been discovered is that the autologous cells will outperform somebody elses cells inside ones body. This is not fully understood yet. It may be that the environment that ones own cells function in, and that they used to that environment. They recognize it. It is the same DNA and they can function well there.

But, once the culture is expanded and a pure population of these mesenchymal cells, not necessarily the sample thats coming right off of the liposuction, but a sample that has been taken to the lab and grown, those cells will not elicit an immune response if you use them in someone else. You could scientifically and medically use those in an unmatched person. However, there are some regulatory aspects of that with regards to the FDA.

In the US, there are a variety of new stem cell products available, referred to as amniotic, cord blood products or placenta products, which are prepared at a tissue bank. Such facilities must be registered with the FDA, and the products must undergo additional processing.

For example, they must be morselized, or snap frozen or blended in some way. Such processing typically breaks the membrane, releasing growth factors, and the resulting products are called acellular, meaning there are no living cells remaining in the sample.

The amniotic products available in the US are not so much stem cell products as they are growth factor products.

Dr. Comella notes: They can be useful in creating an immunomodulatory response, which can help to promote healing, but that still differs from the living stem cell procedures that can be done by either isolating cells from your fat or bone marrow. As a general rule, you do not achieve the clinical benefits when using an amniotic product, primarily because they do not contain living stem cells.

I want to contrast that to what are called embryonic stem cells, Dr. Comella adds. The products obtained from cord blood, from women who are having babies, are not embryonic stem cells. Embryonic stem cells are when you are first bringing the egg and sperm together. Three days after that, you can isolate what is called an inner cell mass. This inner cell mass can be used to then grow cells in culture, or that inner cell mass could eventually lead to the formation of a baby.

Those are embryonic stem cells, and those are pluripotential, meaning that they have the ability to form an entire being, versus adult stem cells or stem cells that are present in amniotic tissue, [which] are multipotential, which only have the ability to form subsets of tissue.

When youre dealing with different diseases or damaged tissue or inflammation, mostly you want to repair tissue. If somebody has damage in their knee, they dont necessarily need embryonic cells because they dont need a baby in their knee. They need new cartilage in their knee.

A common question is whether stem cells can cause overgrowth, leading to cancer or tumor formation.

As noted by Dr. Comella, this is a problem associated with embryonic stem cells, which tend to grow very rapidly and can form a teratoma because of the rapid cell growth. Adult stem cells, the cells obtained from ones own body, have growth inhibitions and will not form teratomas.

The theoretical concern that has been addressed in animal models or in petri dishes is that if you take cancer cells that are growing in a dish and apply stem cells, it may make those cancer cells grow more rapidly. But this does not translate in-vivo to humans.

If there was truly an issue with applying stem cells to a patient who has cancer, we would know about it by now, because weve been dosing cancer patients with stem cells since the 1930s. The safety profile is strong and there are tens of thousands of patients documented with these treatments, Dr. Comella says.

Another useful therapy is platelet-rich plasma (PRP).

Our peripheral blood contains platelets, which act as 1st responders when theres an injury. They come in and start the clotting mechanism, thereby preventing one from bleeding to death. They also give marching orders to other cells.

For example: platelets can command stem cells to multiply and grow, or to differentiate and form new tissue.

These platelets also have many different growth factors associated with them, which can help to promote healing and stop inflammation. PRP involves taking a blood sample and then spinning the blood in a centrifuge to isolate the platelets. The platelet-rich plasma is then injected back into the area that is inflamed.

One of the most common uses of platelet-rich plasma or PRP is in a joint. Now, platelets are going to be most successful in something that is rich in stem cells [such as] an acute or a very recent injury.

If you just hurt your knee, the first thing you should do is get PRP, because its going to help promote healing, and those platelets will attach to the surface receptors of the stem cells that are already going to the area to promote healing. It would be like putting fertilizer on your seed, which are the stem cells.

If you have something more chronic, this tends to be a stem cell-poor environment. In other words, you have osteoarthritis or youve got knee pain thats 5 years old and its been there for a long time; just putting PRP in it would be like putting fertilizer on dirt without planting a seed first.

The beauty of stem cell therapy is that it mimics a process that is ongoing in the human body all the time. Our stem cells are continuously promoting healing, and they do not have to be manipulated in any way. The stem cells naturally know how to home in on areas of inflammation and how to repair damaged tissue.

All were doing is harnessing the cells from one location where theyre sitting dormant and relocating them to exactly where we want them and we need them to work, Dr. Comella says. Basically, anything inside your body that is inflamed, that is damaged in some way, that is lacking blood supply, the [stem] cells can successfully treat.

That means orthopedics, knee injections, shoulder injections, osteoarthritis, acute injuries, anterior cruciate ligament tears in the back, back pain associated with degenerative disc disease or damaged tendons or ligaments, herniated and bulging discs. You can also use it in systemic issues, everything from diabetes, to cardiac, to lungs, any tissue organ inside your body that has been damaged.

Autoimmune diseases can also be treated. The stem cells are naturally immunosuppressant, meaning they can help quiet down an over reactive immune system and help the immune system function in a more normal way. Neurological diseases, traumatic brain injury, amyotrophic lateral sclerosis, Parkinsons. All of these have to do with tissue thats not functioning properly. The cells can be used to address that.

It is very impressive, the list of different diseases that could benefit from this intervention.

Again, it is not magic, but one can dramatically improve the benefits of this intervention by combining it with other healthy lifestyle factors that optimize mitochondrial function, such as eating a healthy Real food diet, exercising, sleeping well, avoiding toxins and detoxifying from toxic influences.

Stem Cells for Anti-Aging: Stem cells can also be used as part of an anti-aging program.

Dr. Comella has used stem cells on herself for several years, and report feeling better now than she did 10 year ago.

She writes,The ability to reduce inflammation inside your body is basically making yourself live longer. Inflammation is what kills us all. Its what makes our telomeres shrink. Its what causes us pain and discomfort. Its what makes the tissues start to die. The ability to dose yourself with stem cells and bring down your inflammation, which is most likely caused by any sort of toxin that youve been exposed to, breathing air is exposure to toxins, this is going to lengthen your lifespan.

I typically will do a dose every six to 12 months, regardless of whats going on. If I have anything that is bothering me, if I tweak my knee at the gym, then I absolutely will come in and do an injection in my knee. I want to keep my tissue healthy for as long as possible.

I want to stay strong. I dont want to wait until something is wrong with me. I think that this is the future of medicine. This is what were going to start to see. People will begin to get their regular doses of [their own] stem cells and itll just be common practice.

Keep in mind theres a gradual and progressive decline in the quality and the number of stem cells as we age, so if considering this approach, it would be to your advantage to extract and bank your stem cells as early on as possible. US Stem Cell provides a stem cell bank service, so one can store them until a later date when you might need them.

Your stem cells are never as young as they are right now. Every minute that you live, your telomeres are shrinking. The ability to lock in the youth of your cells today can be very beneficial for you going forward, and for your health going forward. God forbid something happens. What if you have a heart attack? Youre not going to get clearance to get a mini-lipo aspirate procedure.

If you have your cells waiting in the bank, ready for you, it becomes very easy to pull a dose and do an IV delivery of cells. Its almost criminal that were not doing this for every single one of our cardiac patients. This should be standard practice. We should be having every single patient bank their stem cells at a young age and have them waiting, ready and available. The technology is there. We have it. Im not sure why this technology is not being made available to everyone, she says.

I think stem cell therapy is very different than traditional medicine. Stem cell therapy may actually make it so that you dont have to be dependent on pharmaceutical medications. You can actually repair the tissue and thats it. This is a very different way of viewing medicine.

For a Physician in your area providing the service, you can go there. US Stem Cell can help you locate a qualified doctor.

Eat healthy, Be healthy, Live lively

blood, bodies, body, cell, cells, damage, grow, help, knee, patients, regenerate, repair, stem, tissue, USRM

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Go here to see the original:
Stem Cell Therapy: Repair and Regenerate Our Bodies - Live ... - Live Trading News

Posted in Cell Therapy | Comments Off on Stem Cell Therapy: Repair and Regenerate Our Bodies – Live … – Live Trading News

CAR T-Cell Therapy Effective in Multiple Myeloma – Cancer Network

Posted: June 10, 2017 at 3:44 am

Wanhong Zhao, MD, PhD, presenting results of the study; photo by ASCO/Scott Morgan 2017

A new type of immunotherapychimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation protein (BCMA)may be a new effective type of treatment for patients with multiple myeloma, according to the results of a single-arm study (abstract LBA3001) presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 26.

Our results show clinical and reproducible therapeutic efficacy in refractory or relapsed multiple myeloma disease, said Wanhong Zhao, MD, PhD, an associate director of hematology at the Second Affiliated Hospital of Xian Jiaotong University in China, who presented the results.

With longer than 1 year of follow-up, early patients enrolled on the study are showing durable and stringent complete remissions, according to Zhao.

In recent years, CAR T-cell therapy targeting CD19 has been shown to be very effective in trials of acute lymphoblastic leukemia. However, there had been little success with CAR T-cell therapy targeting other biomarkers in other types of cancer.

Zhao and colleagues conducted a single-arm trial to assess the safety and efficacy of this treatment approach in patients with multiple myeloma. The presentation included data from the first 35 patients enrolled in the ongoing trial.

The overall response rate was 100%; 33 of the 35 patients (94%) had clinical remission of myeloma, with either complete response or very good partial response occurring within 2 months of undergoing CAR T-cell therapy. First signs of efficacy appeared as early as 10 days after treatment initiation.

Of the 35 patients, 19 have been followed for longer than 4 months. Of these patients, 14 have reached stringent complete response, 4 patients have achieved very good partial response, and 1 patient has achieved partial response.

In addition, there are 5 patients who have been followed for longer than 1 year; all of these patients remain in stringent complete remission and are free of minimal residual disease.

Cytokine release syndrome (CRS) is a common adverse effect related to CAR T-cell therapy. CRS occurred in 85% of patients. Among the 35 patients, 6 patients remained free of any CRS; 17 had grade 1, 10 had grade 2, and 2 had grade 3. No grade 4 or 5 CRS occurred and there were no treatment-related deaths.

According to Zhao, a US clinical trial of this technology is currently underway.

Commenting on the results of this study, ASCO Expert Michael S. Sabel, MD, FACS, of the University of Michigan, said that these results were revolutionary and show that immunotherapy is beginning to provide hope to patients with cancers that are not responding to standard chemotherapy.

You are now seeing a merger of immunotherapy with precision therapy and this is the epitome of personalized medicine, Sabel said. Now you see the ability to combine personalized medicine and immunotherapy to gear T cells to recognize patients own specific tumor. This opens the door to using precision immunotherapy to expand the potential of immunotherapy to a wider net of patients.

Read more:
CAR T-Cell Therapy Effective in Multiple Myeloma - Cancer Network

Posted in Cell Therapy | Comments Off on CAR T-Cell Therapy Effective in Multiple Myeloma – Cancer Network

Page 86«..1020..85868788..100110..»